BioAsset

Insights / All articles

Research

Fast-Tracked: How Hernexeos Won FDA Approval in 44 Days

By Alay Galvankar, Lead Analyst & Vice President at BioAsset · 5 slides

Boehringer Ingelheim’s lung cancer drug Hernexeos (zongertinib) won FDA approval on January 13th, just 44 days after receiving a special voucher on November 6th. It was the second drug approved under the FDA Commissioner’s National Priority Voucher (CNPV) program, which is built to shorten reviews for drugs that match national priorities.

The voucher behind the speed

Launched in June 2025, the CNPV program is a pilot initiative aimed at dramatically cutting drug review timelines, from 10 to 12 months down to just 1 to 2 months. It targets drugs that align with key national priorities, including responses to public health emergencies, efforts to bring pharmaceutical manufacturing back to the U.S., and improving the affordability of medications.

Clinical trial data submitted to the FDA showed that 76% of previously untreated patients experienced a meaningful reduction in tumor size. Existing standard-of-care treatments see a response rate of roughly 30 to 45%.

FDA Commissioner Marty Makary said of the approval that patients and sponsors deserve “an efficient FDA process that cuts out idle time” and delivers powerful treatments safely and quickly for the American people.

A small market with strong revenue density

Lung cancer is the leading cause of cancer deaths in the U.S. and the second most common cancer in men and women. The American Cancer Society estimates approximately 230,000 new lung cancer cases and 125,000 lung cancer deaths in 2026.

Hernexeos addresses a narrow slice of that group. About 85% of lung cancers in the U.S. are non-small cell lung cancer (NSCLC), and HER2 mutations account for roughly 4% of NSCLC, or about 3.4% of all lung cancers. That means 4,000 to 8,000 new U.S. patients a year. The population is small, but this is a high-value precision oncology niche: annual therapy costs run $150K to $250K or more per patient.

The current commercial competitor is Enhertu, from AstraZeneca and Daiichi Sankyo, a HER2-directed antibody-drug conjugate given by intravenous infusion every three weeks. Hernexeos is an oral, selective HER2 inhibitor. It has an opportunity to move into first-line treatment, where it could compete directly with chemo-immunotherapy in HER2-positive patients, and earlier-line adoption would mean a larger addressable revenue pool. Experts project peak revenue of approximately $1B, based on a $100,000 price tag and 10,000 eligible patients. The drug also adds to the trend of treating lung cancer based on specific genetic mutations rather than one general approach.

What the approval sets in motion

The approval is expected to change both the way lung cancer is treated and the market for lung cancer therapies. Strong early efficacy from Hernexeos sets a high bar for follow-on therapies. It also validates HER2 mutations as a target, which should draw big pharma companies to develop their own rival treatments over the next few years.

There is a caveat. Hernexeos has accelerated approval based on early clinical trial data, so it carries some regulatory risk until confirmatory trials succeed. Even so, Boehringer now has a several-year lead in HER2-mutant therapy, which lets the company influence guidelines and everyday use.

What the CNPV means for pharma

Faster approvals let pharma companies launch products sooner in lucrative markets and capture earlier sales for high-demand drugs such as oncology treatments or antibiotics. The program’s qualifiers target public health crises, breakthrough therapies, unmet needs, supply chain resilience and affordability, covering areas like cancer, obesity and gene therapies. Unlike Priority Review Vouchers (PRVs), which are transferable, CNPVs cannot be sold, but they are strategically superior for U.S.-focused pipelines.

The U.S. pharmaceutical market has maintained a strong upward trajectory over the past two years. State Street’s XPH, a commonly referenced pharmaceutical ETF, is up almost 32% over the past year, at $57.56 according to Google Finance. For reference, it stood at $40.75 on June 17th, 2025, the day the CNPV went into effect.

With the CNPV now in place, companies have a unique window to significantly accelerate their drug development timelines and reach the market sooner. Other medications that have completed or are completing the CNPV process include Wegovy (obesity), Casgevy (sickle cell) and Bedaquiline (drug-resistant TB).

This article is the text version of a BioAsset slide post. See the original slides on bioasset.info.